Cypress Bioscience Inc. (CYPB.O) on Tuesday announced that it was discontinuing development for a treatment of obstructive sleep apnea. This decision followed results of a mid-stage trial that found the results of the drug unsatisfactory.
Cypress and Organon, a unit of Akzo Nobel (AKZO.AS), had each independently conducted Phase IIa trials evaluating combinations of mirtazapine with another approved drug.
The companies are exploring other opportunities for collaboration, Cypress added.
Leave a comment